Business Context and Reporting Period
Company: Karyopharm Therapeutics Inc. (KPTI)
Filing Type: Form 8-K (Current Report)
Date of Report: October 7, 2025
Reporting Period: The filing details a series of "Financing Transactions" entered into on October 7, 2025, expected to close on or around October 10, 2025. It also provides preliminary financial estimates for the quarter ended September 30, 2025.
Key Financial Metrics and Capital Structure
Capital Raised and Flexibility:
- Total Financial Flexibility: $100 million provided through a combination of new capital, deferrals, and covenant adjustments.
- Expected Cash Proceeds: Approximately $36.0 million (before transaction expenses).
- Private Placement Proceeds: $8.75 million gross proceeds from the sale of common stock and warrants.
Debt and Liquidity Position (Post-Transaction):
- Senior Secured Term Loan: $112.5 million outstanding (maturity May 2028).
- Convertible Notes (2028): $15.0 million aggregate principal (9.00% interest).
- Convertible Notes (2029): $103.5 million aggregate principal (9.00% interest).
- Convertible Notes (2025): Approximately $0.25 million remaining principal.
- Revenue Interest Financing (HCRx): $116.2 million maximum remaining payments.
- Cash Balance (Preliminary): Approximately $46 million as of September 30, 2025.
Revenue Estimates (Q3 2025):
- Total Revenue: Estimated range of $42.0 million to $44.0 million.
- U.S. XPOVIO (selinexor) Net Product Revenue: Estimated at approximately $32.0 million.
Equity Issuance:
- New Shares Issued: 7,223,982 shares of common stock.
- Pre-funded Warrants: 2,913,136 shares.
- Warrants Issued: 5,918,358 shares (exercise price $6.64).
- Warrant Price Reduction: Existing warrants for 3,068,417 shares reduced from $16.50 to $6.64.
- Post-Transaction Shares Outstanding: Expected to be 15,926,939 (excluding warrant exercises/conversions).
Material Changes vs. Prior Period
Debt Restructuring and Equitization:
- 2025 Notes: $24.25 million of maturing notes exchanged for common stock, pre-funded warrants, and new warrants.
- 2029 Notes: $15.0 million of old notes exchanged for common stock and pre-funded warrants; remaining $101.0 million exchanged for new 9.00% notes due 2029.
- Interest Rate Increase: Term loan interest rate increased to SOFR + 10.25% for payments after June 30, 2025.
- Payment Deferrals: Approximately $25 million in near-term interest and royalty payments deferred. Cash interest payments on term loans and convertible notes will not begin until June 30, 2026.
Covenant Adjustments:
- Liquidity Covenant: Temporary reduction of the minimum liquidity covenant by $15.0 million. The covenant requires maintaining liquidity of at least $25 million after October 10, 2026.
Revenue Interest Financing (HCRx):
- Rate Increase: Applicable Tiered Percentage increased to 8.00% starting April 1, 2026.
- Payment Waivers: Revenue interest payments waived for August 15, 2025, through May 15, 2026.
Guidance, Outlook, and Management Commentary
Operational Outlook:
- Runway: The Financing Transactions are expected to fund current operating plans into the second quarter of 2026.
- Clinical Trials: Proceeds will support ongoing and planned clinical trial activities. Top-line data from the Phase 3 SENTRY trial of selinexor is expected in March 2026.
Management Actions:
- Retention Program: Implemented a retention program for executive officers and key employees. Includes RSUs for the CEO, CFO, and CCO, and a $1.0 million cash retention bonus for the CMO. Total expected retention cash bonuses are approximately $9.0 million ($2.0 million company-wide + $7.0 million performance-based).
- Board Observer: The Company agreed to appoint a non-voting observer to the Board of Directors selected by the Lenders.
Risks and Contingencies:
- Registration Rights: The Company must file a registration statement for resale of securities within 45 days of closing. Failure to do so triggers liquidated damages of 1% of the aggregate notional amount per 30-day default period.
- Ownership Caps: Conversion and exercise of notes and warrants are subject to 4.99% ownership limitations (unless holders provide notice to increase to 19.99%).
Investor Verification Checklist
- Closing Confirmation: Verify the actual closing date and final cash proceeds received, as the filing states transactions are expected to close "on or around" October 10, 2025.
- Dilution Impact: Confirm the final number of shares outstanding post-closing, including the impact of pre-funded warrant exercises and any immediate conversions.
- Interest Expense: Review the impact of the increased interest rate (SOFR + 10.25%) and the deferral of cash interest payments until June 2026 on future cash flow projections.
- Revenue Accuracy: Compare the preliminary Q3 2025 revenue estimates ($42M-$44M total) against the final audited figures in the upcoming 10-Q.
- Registration Statement: Monitor the filing of the registration statement for the new securities within the 45-day deadline to avoid liquidated damages.
- Covenant Compliance: Track the Company's liquidity position to ensure it meets the $25 million minimum liquidity covenant effective October 10, 2026.